Caffeine and progression of Parkinson disease

A deleterious interaction with creatine

David K. Simon, Cai Wu, Barbara C. Tilley, Anne Marie Wills, Michael J. Aminoff, Jacquelyn Bainbridge, Robert A. Hauser, Jay S. Schneider, Saloni Sharma, Carlos Singer, Caroline M. Tanner, Daniel Truong, Pei Shieen Wong

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake. Methods: Data were analyzed from a large phase 3 placebo-controlled clinical study of creatine as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 movement disorders centers across the United States and Canada. A total of 1741 subjects with PD participated in the primary clinical study, and caffeine intake data were available for 1549 of these subjects. The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified ParkinsonDisease Rating Scale score and the interaction of this association with creatine intake were assessed. Results: Caffeine intake was not associated with the rate of progression of PD in the main analysis, but higher caffeine intake was associated with significantly faster progression among subjects taking creatine. Conclusions: This is the largest and longest study conducted to date that addresses the association of caffeine with the rate of progression of PD. These data indicate a potentially deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.

Original languageEnglish (US)
Pages (from-to)163-169
Number of pages7
JournalClinical Neuropharmacology
Volume38
Issue number5
DOIs
StatePublished - Oct 1 2015

Fingerprint

Creatine
Caffeine
Parkinson Disease
Movement Disorders
Canada
Placebos

Keywords

  • Adenosine A2a receptor antagonist: LS1
  • Association
  • Caffeine
  • Clinical study
  • Coffee
  • Creatine
  • Interaction
  • Movement disorders
  • NET-PD
  • Neuroprotection
  • Parkinson disease
  • Progression
  • Supplement

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

Simon, D. K., Wu, C., Tilley, B. C., Wills, A. M., Aminoff, M. J., Bainbridge, J., ... Wong, P. S. (2015). Caffeine and progression of Parkinson disease: A deleterious interaction with creatine. Clinical Neuropharmacology, 38(5), 163-169. https://doi.org/10.1097/WNF.0000000000000102

Caffeine and progression of Parkinson disease : A deleterious interaction with creatine. / Simon, David K.; Wu, Cai; Tilley, Barbara C.; Wills, Anne Marie; Aminoff, Michael J.; Bainbridge, Jacquelyn; Hauser, Robert A.; Schneider, Jay S.; Sharma, Saloni; Singer, Carlos; Tanner, Caroline M.; Truong, Daniel; Wong, Pei Shieen.

In: Clinical Neuropharmacology, Vol. 38, No. 5, 01.10.2015, p. 163-169.

Research output: Contribution to journalArticle

Simon, DK, Wu, C, Tilley, BC, Wills, AM, Aminoff, MJ, Bainbridge, J, Hauser, RA, Schneider, JS, Sharma, S, Singer, C, Tanner, CM, Truong, D & Wong, PS 2015, 'Caffeine and progression of Parkinson disease: A deleterious interaction with creatine', Clinical Neuropharmacology, vol. 38, no. 5, pp. 163-169. https://doi.org/10.1097/WNF.0000000000000102
Simon, David K. ; Wu, Cai ; Tilley, Barbara C. ; Wills, Anne Marie ; Aminoff, Michael J. ; Bainbridge, Jacquelyn ; Hauser, Robert A. ; Schneider, Jay S. ; Sharma, Saloni ; Singer, Carlos ; Tanner, Caroline M. ; Truong, Daniel ; Wong, Pei Shieen. / Caffeine and progression of Parkinson disease : A deleterious interaction with creatine. In: Clinical Neuropharmacology. 2015 ; Vol. 38, No. 5. pp. 163-169.
@article{519f94cf7e484405a2421486825b0534,
title = "Caffeine and progression of Parkinson disease: A deleterious interaction with creatine",
abstract = "Objective: Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake. Methods: Data were analyzed from a large phase 3 placebo-controlled clinical study of creatine as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 movement disorders centers across the United States and Canada. A total of 1741 subjects with PD participated in the primary clinical study, and caffeine intake data were available for 1549 of these subjects. The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified ParkinsonDisease Rating Scale score and the interaction of this association with creatine intake were assessed. Results: Caffeine intake was not associated with the rate of progression of PD in the main analysis, but higher caffeine intake was associated with significantly faster progression among subjects taking creatine. Conclusions: This is the largest and longest study conducted to date that addresses the association of caffeine with the rate of progression of PD. These data indicate a potentially deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.",
keywords = "Adenosine A2a receptor antagonist: LS1, Association, Caffeine, Clinical study, Coffee, Creatine, Interaction, Movement disorders, NET-PD, Neuroprotection, Parkinson disease, Progression, Supplement",
author = "Simon, {David K.} and Cai Wu and Tilley, {Barbara C.} and Wills, {Anne Marie} and Aminoff, {Michael J.} and Jacquelyn Bainbridge and Hauser, {Robert A.} and Schneider, {Jay S.} and Saloni Sharma and Carlos Singer and Tanner, {Caroline M.} and Daniel Truong and Wong, {Pei Shieen}",
year = "2015",
month = "10",
day = "1",
doi = "10.1097/WNF.0000000000000102",
language = "English (US)",
volume = "38",
pages = "163--169",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Caffeine and progression of Parkinson disease

T2 - A deleterious interaction with creatine

AU - Simon, David K.

AU - Wu, Cai

AU - Tilley, Barbara C.

AU - Wills, Anne Marie

AU - Aminoff, Michael J.

AU - Bainbridge, Jacquelyn

AU - Hauser, Robert A.

AU - Schneider, Jay S.

AU - Sharma, Saloni

AU - Singer, Carlos

AU - Tanner, Caroline M.

AU - Truong, Daniel

AU - Wong, Pei Shieen

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objective: Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake. Methods: Data were analyzed from a large phase 3 placebo-controlled clinical study of creatine as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 movement disorders centers across the United States and Canada. A total of 1741 subjects with PD participated in the primary clinical study, and caffeine intake data were available for 1549 of these subjects. The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified ParkinsonDisease Rating Scale score and the interaction of this association with creatine intake were assessed. Results: Caffeine intake was not associated with the rate of progression of PD in the main analysis, but higher caffeine intake was associated with significantly faster progression among subjects taking creatine. Conclusions: This is the largest and longest study conducted to date that addresses the association of caffeine with the rate of progression of PD. These data indicate a potentially deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.

AB - Objective: Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake. Methods: Data were analyzed from a large phase 3 placebo-controlled clinical study of creatine as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 movement disorders centers across the United States and Canada. A total of 1741 subjects with PD participated in the primary clinical study, and caffeine intake data were available for 1549 of these subjects. The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified ParkinsonDisease Rating Scale score and the interaction of this association with creatine intake were assessed. Results: Caffeine intake was not associated with the rate of progression of PD in the main analysis, but higher caffeine intake was associated with significantly faster progression among subjects taking creatine. Conclusions: This is the largest and longest study conducted to date that addresses the association of caffeine with the rate of progression of PD. These data indicate a potentially deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.

KW - Adenosine A2a receptor antagonist: LS1

KW - Association

KW - Caffeine

KW - Clinical study

KW - Coffee

KW - Creatine

KW - Interaction

KW - Movement disorders

KW - NET-PD

KW - Neuroprotection

KW - Parkinson disease

KW - Progression

KW - Supplement

UR - http://www.scopus.com/inward/record.url?scp=84941889182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941889182&partnerID=8YFLogxK

U2 - 10.1097/WNF.0000000000000102

DO - 10.1097/WNF.0000000000000102

M3 - Article

VL - 38

SP - 163

EP - 169

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 5

ER -